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The cytokine interleukin-l0 (IL-10) has been implicated in the pathogenesis of a number of disease states, including Epstein-Barr virus and human immunodeficiency virus (HIV-1) infections. In the acquired immunodeficiency syndrome (AIDS), it has been suggested that IL-10 may have a deleterious effect by suppressing cell-mediated immunity. However, there are few data on its direct d e c t s on HIV-1 replication. In the present study, we have found that recombinant human IL-10 (rhlL-10). present during days 0 through 2. potently inhibits HIV production in elutriated monocyte/macrophage (MIM) cultures with a 50% inhibitory concentration (ICso) of approximately 0.03 UlmL. This effect did not appear t o be caused by toxicity t o M/M because there was no change in cell viability, ability to phagocytose latex beads, or protein synthesis as measured by [3Hl-leucine incorporation, at doses of rhlL-l0 that inhibit viral replication. In addition, lipopolysaccharide-induced production of IL-lp, IL-6, or tumor necrosis factor-cu was not affected at these doses, HE CYTOKINE interleukin-10 (IL-10; previously called cytokine synthesis inhibitory factor) was initially identified in 1989 as a factor secreted by murine Th2 cell clones that inhibits the secretion of interferon-y (IFNy ) and other cytokines by Thl cells.' In addition, IL-10 appears to mediate some of the B-cell stimulatory effects of Th2 cells in the mouse, and this cytokine thus appears to be involved in shifting the balance of an immune response away from cellular immunity and towards humoral Additional studies have shown IL-IO to have immunomodulatory effects by acting on macrophages and other cell types. In particular, IL-10 suppresses the secretion of various cytokines by activated macrophages: ' costimulates mast cell growth,6 and costimulates thymocyte growth in the presence of IL-2 andor IL-4.' Soon after the discovery of murine IL-10 (mIL-IO), the human IL-l0 (hIL-10) gene was identified and cloned.' hIL-10 has been found to be produced by cells of several lineages, including B and T lymphocyte^^^"' and monocyte/macrophages (M/M).'~" In a number of aspects, the activity of hlL-l0 parallels that of mIL-10; it inhibits Tcell responses,12 suppresses cytokine production by and stimulates B cells to produce Ig. 13 However, there is recent evidence to suggest that hIL-10 may not be as clearly a cytokine of Th2 cells as is mIL-10. In particular, hIL-10 is produced by both Thl-like and Th2-like T-cell clones and it may inhibit antigen-driven activity of both Thl and Th2 subset^.'^,'^,'^ It has recently been reported that the mononuclear cells of human immunodeficiency virus (HIV)-infected patients have increased IL-l0 expression16 and that disease progression is associated with an increase in the capacity of lymphocytes to produce IL-4 and IL-10.'' However, there are no data yet available on serum IL-10 levels in HIV-infected patients. It has also been found that, in a murine experimental model for acquired immunodeficiency syndrome (AIDS) in which immunodeficiency is induced by the LP-BM5 murine leukemia virus, IL-l0 overexpression is associated with Bcell hyperactivation, downregulation of Thl cytokine secretion, and impaired CD8+ T-cell function.'* More recently, it nor were human mononuclear cell proliferative responses to phytohemagglutinin, OKT3 antibody, or tetanus toxoid. HIV-1 replication was similarly decreased by rhlL-l0 in the monocytoid line U937 without signs of cellular toxicity. However, these effects required much higher concentrations of rhlL-10, and viral production was only partially suppressed. rhlL-l0 also slightly inhibited HIV-induced cytopathicity in ATH-8, a tetanus toxoid-specific, retrovirally immortalized T-cell line, but had no effect on HIV replication in the H9 and MOLT-4 T cell lines. Thus, rhlL-l0 appears to inhibit HIV replication predominantly in cells of the M/M lineage. This effect may serve to reduce viral production in patients with AIDS. However, additional studies w i l l be needed to more precisely define its physiologic role in this disease. This is a US government work. There are no restrictions on its use.
has been reported that IL-4-deficient transgenic mice that lack Th2 cytokine responses are relatively resistant to the development of disease when infected with LP-BM5 virus." Although there are some differences in the target cells of HIV and LP-BM5 and (as noted above) between the murine and human immune system in regard to the delineation of Thl and Th2 subsets, these observations have led to the concept that both human and murine immunodeficiency syndromes are associated with a switch to a Th2-like immune response with associated IL-IO overproduction. However, there are few data available on the effects of IL-10 on HIV replication.
With this background, we have investigated the effects of hIL-IO on HIV replication in M M and T-cell lines. We find that, although this cytokine has modest anti-HIV activity in a CD4+ T-cell line, it potently inhibits viral replication in M/M at concentrations that do not interfere with other critical immune responses. Thus, it is possible that IL-10 production may at least in part have beneficial effects in patients with HIV infection. 10 cDNA-transfected C H 0 cells was used for cultures performed with primary MM.") For studies in lymphocytoid and monocytoid cell lines, rhIL-IO produced by transfected COS-7 cells was used; supernatant from mock-transfected COS-7 cells was used in these experiments as a control. COS-7-produced rhIL-l0 was also used to repeat certain observations made using the CHO-produced rhIL-IO in primary M M . Recombinant mIL-IO (rmIL-IO) was derived from a baculovirus expression system. These IL-10 preparations were a kind gift of Drs K.W. Moore and P. Viera (DNAX Research Institute, Palo Alto, CA). The effect of rhlL-l0 on HIV replication in primary M M was also tested using highly purified rhIL-l0 expressed in an Escherichia coli system (gift of Dr Satwant Narula, Schering Plough Research Institute, Kenilworth, NJ). One unit of IL-10 (human or murine) is defined as the amount that will produce half-maximal stimulation of the MCI9 murine mast cell line.' Human recombinant monocyte colony-stimulating factor (M-CSF; Cellular Products, Buffalo, NY) was used at a concentration of 1,000 UlmL. Lipopolysaccharide (LPS) from E coli strain J 5 RC mutant (Sigma, St Louis, MO) was diluted in medium and used at a final concentration of 1 pg/mL. 2'3'-Dideoxyinosine (ddI; Sigma) and sodium azide (Sigma) were diluted in phosphate-buffered saline (PBS) before use.
Cell culture. Human mononuclear cells were obtained from the peripheral blood of normal HIV-seronegative donors by use of a cell separator (Fenwal C3000; Baxter-Travenol, Deerfield, IL). The cells were then further enriched for MIM by means of countercurrent centrifugal elutriation as previously described.*' The resulting cells were greater than 95% monocytoid when examined after Giemsa staining and were greater than 95% nonspecific esterase positive. Cell viability as evaluated by trypan blue exclusion was consistently greater than 95%. More than 93% of the cells were CD1 1 b' and CD36' ( O M 1 and OKM5, respectively; Ortho Diagnostic Systems, Westwood, MA). Other characteristics of these cells have been described elsewhere. 22 The cells were cultured in 48-or 96-well plates (Costar, Cambridge, MA) in RPMI 1640 medium (GIBCO Laboratories, Grand Island, NY) supplemented with 20% heat-inactivated, low endotoxin fetal calf serum (defined FCS; Hyclone Laboratories, Logan, UT), 2 mmol/L L-glutamine, 50 UImL penicillin, and 50 p g / mL streptomycin (all from GIBCO Laboratories). No proliferationinducing cytokines, such as M-CSF or granulocyte-monocyte CSF (GM-CSF), were used in the experiments unless specifically stated. Infection with HIV-l was performed 4 days after the cells were initially put into culture (vide infra).
Human mononuclear cells were obtained by Ficolllsodium diatrizoate (LSM; Organon Teknica, Durham, NC) density centrifugation of peripheral blood from normal, HIV-seronegative donors. THP-I , MOLT-4, and U937 cells were obtained from American Type Culture Collection (ATCC; Rockville, MD). The H9 cell line was a gift of M. Popovic and R. Gallo (Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD). The cells were all cultured in 96-well plates in RPMI 1640 medium supplemented with 10% heat-inactivated, low endotoxin FCS, 2 mmol/L L-glutamine, 50 U/ mL penicillin, and 50 pgImL streptomycin. ATH-8 cells, a tetanustoxoid-specific CD4' T-cell line immortalized by exposure to human T-cell lymphocytotropic virus type I (HTLV-I)2"24 (gift of H. Mitsuya, National Cancer Institute) were propagated in the above medium with the addition of 50 U/mL rhIL-2 (R and D Systems, Minneapolis, MN) and 20% purified delectinized hIL-2 (Advanced Biotechnologies, Inc, Columbia, MD). All cell lines were tested and found to be negative for Mycoplasma contamination.
Viral strains. HIV-IBa~,, a monocytotropic strain of HIV-1 (a kind gift of Drs S. Gartner, M. Popovic, and R. Gallo, National Cancer Institute) was used at a dose of 400 X TCID,,, (tissue culture infectious dose) for all experiments in primary M M . Infectivity was determined in primary M/M cultures, as previously described.22 HIV-1 ll,B :5 a lymphocytotropic strain (Advanced Biotechnologies, Inc) was used for other studies. Doses of 3,000 X TCIDSn in ATH-8 and 1,000 X TCIDSO in H9, MOLT-4, THP-1, and U937 cell lines were used. The infectivity of HIV-lIIIB was determined using the ATH-8 cell line.24,26 Viral doses were chosen to produce greater than 90% cell lysis in ATH-8 cells, and high-titer, reliable infection in the other cell lines.
Cytokirze and virus quantirarion. Measurement of 1L-Ip and tumor necrosis factor-cy (TNF-a) in culture supernatant was performed by enzyme-linked immunosorbent assay (ELISA; obtained from R and D Systems) after viral inactivation with Triton-X 100 at a final concentration of 0.58. Lower limits of detection for IL-I,G and TNF-(Y were 3.90 pgImL and 15.7 pg/mL, respectively. IL-6 was quantitated by bioassay, using the IL-6-dependent lymphocytic cell line B9 after heat-inactivation of virus at 55°C for 30 minutes. as de~cribed.*'~*~ Viral production was assessed by HIV-I p24 antigen (gag) release into culture supernatants as measured by radioimmunoassay (Du Pont CO, Wilmington, DE); the lower limit of detection was 600 pg/ mL. In some experiments, viral production was also assessed by an assay of reverse transcriptase activity (RT-Detect; Du Pont). The cultures were inspected daily by inverted-stage microscopy for ayncytia formation and other viral-and cytokine-induced morphologic effectr.
Monocyte virul suppression assay. The assessment of the effects of rhIL-10 on HIV replication in M M was performed as a modification of a previously published pr~cedure.'~ Elutriated MIM were cultured in complete medium at a concentration of 1.25 X I O 5 cells/ mL, in flat-bottomed 96-well culture plates (Costar, Cambridge, MA) for 4 days before infection (starting on day -4), and incubated at 37°C in a humidified 5% CO2 atmosphere. IL-l0 was added at day -2. 0, +5, or +15, and cells were washed extensively to remove the cytokine 48 hours later. On day 0, virus was added to each well (when IL-l0 was added at day -2, virus was added just after the cytokine was washed out; when L 1 0 was added at day 0, virus was added immediately after the addition of the cytokine). On day 2, cells were washed to remove excess virus (and cytokine when added on day 0). Every 5 days, the supernatant was harvested from each well and replaced with fresh complete medium until day +27 was reached. Supernatants were assayed for HIV-I p24 antigen.
Because peak p24 levels are generally noted at day + 12 in control wells. we focused on this time point in evaluating the effects of IL-10.
M/M phagocytosis. A modification of the method of Malorny et aI3" was used to determine the effect of rhIL-IO on iWM phagocytosis, Elutriated MIM (2.5 X IO5 cellsIl.0-mL well) were cultured in 48-well plates (Costar) for 4 days at 37°C in a humidified 5% CO? atmosphere, with or without rhIL-IO. After 2 days, the wells were washed to remove IL-10 and complete medium was added. Twentyfour hours later, the cells were detached using trypsin and suspended at 1.5 X 10' cells/50 pL in medium using 10 X 75 mm borosilicate glass tubes (Kimble, Vineland, NJ). Twenty-five microliters of a l:20 dilution of 0.8-pm latex beads (Sigma) in complete medium was added to each tube, vortexed, and incubated at 37°C for 45 minutes. After incubation, the cell suspension was layered over 1.5 mL FCS and centrifuged at 250g for 10 minutes at room temperature. Serum and nonphagocytosed beads were removed, and the cells were washed twice with PBS containing 2% bovine serum albumin and 0.02% sodium azide. Cells found to have ingested three or more beads on microscopic examination were scored as positive for phagocytic activity.
Leucine incorporation assay. Incorporation of ['HI-leucine in monocytes was measured using a modification of the procedure of Bonifacino." Monocytes were cultured on 48-well plates (2.5 X 10' cells/l.O-mL well) for 4 days at 37°C in a humidified 5%. CO, atmosphere. The cells were washed, medium containing purified For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From rhIL-l0 or control medium was added, and plates were incubated for 48 hours at 37°C in a 5% COz atmosphere. The cells were again washed, 1, OOO U/mL M-CSF or 0.02% sodium azide was added to certain wells as a positive and negative control for protein synthesis, and the cells were incubated for 12 hours. The cells were washed with leucine-free medium (RPM1 1640 without leucine; GIBCO) supplemented with 20% dialyzed fetal bovine serum and 2 mmol/L L-glutamine (GIBCO) and incubated for 3 hours in this medium with 0.2 mCi/mL [3H]-leucine (Amersham, Arlington Heights, IL). After incubation, proteins were precipitated with 1:l ice-cold 10% trichloroacetic acid (TCA), followed by 30 minutes of incubation at 4°C. Precipitated proteins were collected on glass fiber filters, and washed three times with cold 10% TCA and then twice with absolute ethanol. The filters were dried and counted in scintillation cocktail. At least three replicate wells were established for each data point.
Human peripheral blood mononuclear cell proliferative responses. Freshly isolated human peripheral blood mononuclear cells were washed and cultured at a density of 1 X 106/mL in 200-pL wells in 96-well round-bottom plates with various concentrations of rhIL-IO. Where indicated, 0.5 or 5.0 pg/mL phytohemagglutinin (PHA; Sigma), 1.0 LF/mL tetanus toxoid (Commonwealth of Massachusetts Department of Public Health, Jamaica Plain, NY), or 20 ng/mL mouse anti-human CD3 monoclonal OKT3 antibody (a gift of Ortho Pharmaceutical Corp, Raritan, NJ) were added as stimulators. A relatively low concentration of PHA (0.5 pg/mL) was used along with the higher dose of 5.0 pg/mL, because the suppression of PHA-induced proliferation by rhIL-l0 has been shown to be more evident with lower doses of mitogen." Triplicate wells were established for each condition examined. Plates were incubated for 3 days for PHA stimulation and 5 days for the other proliferative stimuli at 37°C in a humidified 5% CO2 atmosphere. The plates were pulsed with 1.0 pCi r3H]-thymidine during the final 18 hours of incubation. The cultures were then harvested onto glass fiber filters and counted in liquid scintillation cocktail.
Assay of HIV replication in cell lines. Uninfected or chronically HIVIIIB-infected cell lines in exponential growth phase were washed and cultured at a density of 5.0 X lo3 cells/mL in 200-pL wells in 96-well flat-bottom culture plates (Costar). This relatively low cell density was chosen to prevent overgrowth of the culture by the end of the experiment. COS-7 supernatant containing rhIL-IO, mocktransfected COS-7 supematant, mIL-IO at 20 U/mL, or control medium was added as indicated, followed within 30 minutes by an inoculum of HIV-I (1,000 X TCID,,). The plates were incubated for 5 days at 37°C in a humidified 5% COz atmosphere. Supernatants were then harvested for p24 antigen determination, and the cells were counted by hemocytometer using trypan blue. The percentage of suppression is expressed as (1 -[p24 antigenll.,o_l,,,d/p24 antiInhibition assay for the cytopathic effect of HIV-1. The assay was performed as a modification of the method of Mitsuya et aLZ4 ATH-8 cells were cultured at a density of 2.5 X lo5 cells/mL in 96-well U-bottom plates with human or murine IL-l0 at a concentration of 20 U/mL, 20 pmoVL ddl (Sigma), or control medium. After 30 minutes, the cells were inoculated with HIV (3,000 x TCID,,) and incubated at 37°C in a 5% COz atmosphere for 7 days. Viable cells were counted using trypan blue exclusion, and the data were expressed as the percentage of viable cells as compared with uninfected, untreated controls.
Statisfical analysis. Statistical comparisons were performed with Systat for the Macintosh (Systat, Inc, Evanston, IL). Paired or independent Student's t-tests were used as appropriate; all P values are two-tailed. No corrections for multiple comparisons were made. ge&o.uod) x 100%.
RESULTS
rhIL-l0 suppresses HIV replication in M/M. In initial experiments designed to evaluate the effects of rhIL-10 on HIV replication, M/M obtained by elutriation were precultured in complete medium for 4 days and then simultaneously exposed to purified rhIL-l0 (expressed in CH0 cells) and 400 TCID,, HIVBa.L (day 0). After 2 days, the cells were washed extensively and cultured for another 10 days without additional cytokine or virus. As shown in Fig 1, rhIL-l0 (present from day 0 to 2) strongly inhibited p24 production at day 12 in a dose-dependent manner, with an IC5,, of approximately 0.1 to 0.03 U/mL. This effect was statistically significant ( P < .05) for doses of 0.1 U/mL or greater. A comparable effect was seen when reverse transcriptase in the supernatants was assayed as an alternate measure of viral replication (results not shown). Also, similar results were seen with rhIL-l0 as COS-7 supernatant and with purifled rhIL-l0 produced in E coli (data not shown). In control experiments, rmIL-l0 was approximately 30 times less active than rhIL-l0 (results not shown).
The time course of p24 production in cultures exposed to rhIL-l0 on days 0 to 2 is depicted in Fig 2; a representative experiment is shown for clarity, because HIV replication in primary M/M exhibits a 5-to 7-day interexperimental variability in the time to peak viral production. As can be seen, a 2-day exposure of M/M to 0.1 to 1 U/mL of rhIL-10 resulted in a 7 to 10 day delay in the production of HIV. However, rhIL-l0 did not completely abrogate HIV replication in M/M.
Effects of late addition of rhIL-l0 to M/M. In subsequent experiments, we explored the effects of rhIL-l0 added to cultures of M/M previously exposed to HIV. Under the experimental conditions used, the peak of p24 production generally occurs between days 7 and 15. Of seven experiments performed in which rhIL-l0 was added for 2 days at timepoints starting from day 5 to day 15, five showed suppression of HIV replication by rhIL-10; the two remaining experi- For ments were inconclusive because of peaking of HIV replication before the addition of cytokine. Two representative experiments in which rhIL-l0 was added for 2 days starting on day 5 or day 15 are shown in Fig 3. As can be seen, p24 production was suppressed in wells that were exposed to rhIL-10 as compared with control wells. At these later timepoints, productive infection of the cultures is already established, and the results suggest that rhIL-l0 may suppress HIV production in M/M already infected by HIV. However, it is still possible that this late suppression is the result of rhIL-10 interfering with the spread of infection in these cultures,
In additional experiments (not shown), we investigated the effects of rhIL-10 added to M M during the 2 days before the addition of HIV, and then washed out at the time of viral exposure. It was found that, under such conditions, much less inhibition of viral replication was noted. Even at the highest dose tested, p24 antigen production at day 12 was suppressed only 37% as compared with control (results not shown).
Effects of rhIL-l0 on the viability and function of mononuclear cells.
We next asked whether these effects simply resulted from a toxic effect of rhIL-l0 on M/M. As seen in Table I , a 2-day exposure of M/M to rhIL-10 at concentrations of up to 1 U/mL had essentially no effect on the number of viable cells when examined by trypan blue exclusion. Moreover, concentrations of rhIL-l0 up to 1 U/mL had no effect on the ability of M M to phagocytose latex beads. Similar results were seen with HIV-infected MA4 (Table  1) . We also examined the effect of rhIL-l0 on [3H]-leucine incorporation, a measure of protein synthesis in uninfected M/M. Slight inhibition was observed at 1 U/mL of rhIL-l0 (63.1% of control, which was 44,300 cpm), but this did not reach statistical significance ( P = .25). No evidence of decreased incorporation was observed at lower concentrations of rhIL-l0 (108.4% and 114.9% of control at 0 . 1 and 0.01 U/mL, respectively). Thus, HIV replication in M/M was suppressed by rhIL-l0 at concentrations that had little or no effect on the number of viable cells, their phagocytic activity. or their protein synthesis.
Moreover, the lack of cytotoxicity in HIV-infected M M suggests that selective killing of this population is not a mechanism of action of rhIL-l0 in suppressing HIV.
It has been reported' that secretion of various cytokines (including IL-10, IL-6, and TNF-a) by endotoxin-stimulated M/M is inhibited by relatively high concentrations of human IL-10. We were interested to learn whether the lower concentrations of rhIL-l0 found here to inhibit HIV replication in M/M also inhibited production of these cytokines. MIM were placed in either control medium or medium containing rhIL-10, and immediately stimulated with 1 pg/mL LPS. Twelve hours later, the supernatants were harvested and assayed for IL-10, IL-6, and TNF-a. As shown in Table 2 , IL-Io and TNF-a production were marginally decreased by rhIL-10 at the highest concentration used (10 U/mL); however, this effect was not statistically significant. IL-6 production was For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From not affected at any of the doses tested. In additional experiments, we found no effect on the LPS-induced production of IL-6, IL-lp, and TNF-a immediately after or 5 days after a 2-day pulse of rhIL-l0 at concentrations up to 10 U/mL (data not shown). Therefore, rhIL-l0 inhibited HIV replication in M/M at concentrations that had little or no effect on the capacity of monocytes to secrete stimulatory cytokines. As another measure of the immunosuppressive actions of rhIL-l0 at these lower concentrations, we evaluated the effects of rhIL-l0 on mononuclear cell proliferation induced by tetanus toxoid, PHA, and OKT3 monoclonal antibody (anti-CD3). In these experiments, the mononuclear cells were continuously exposed to rhIL-l0 throughout the incubation period, starting at day 0. Even so, there was no significant inhibition of cellular proliferation as measured by ['H]-thymidine incorporation until an rhIL-l0 concentration of 10 U/mL was attained (Table 3 ). These data suggest that the effects of IL-IO on HIV replication in monocytes may occur at a different range of concentrations than those that cause a downregulation of cellular immune functions.
EfSect of rhIL-l0 on HIV replication in T-cell and monocytoid-cell lines. To further characterize the range of cell types in which rhIL-l0 had anti-HIV activity, we examined its ability to suppress HIV replication in the CD4+ T-cell lines H9 and MOLT-4 as well as in the monocytoid lines THP-1 and U937. As seen in Table 4 , a 5-day continuous exposure to 20 U/mL rhIL-IO, starting at the time of infection with HIVlllBr had no effect on HIV p24 production by MOLT-4 or H9 CD4+ T cells. By contrast, 20 U/mL rhIL-10 inhibited HIV production by acutely infected U937 promonocytic cells by 63%. This effect occurred in the absence of any decrease in cell proliferation. rhIL-l0 had little or no effect on THP-l monocytoid cells acutely infected with HIV production (23% decrease). Also, rhIL-l0 had a borderline effect (30% decrease) on constitutive HIV production by U937 cells chronically infected with HIVIIIB. Thus, rhIL-10 can partially inhibit HIV replication in U937 at the relatively high concentration of 20 U/mL.
Finally, we assessed the activity of rhlL-l0 in ATH-8, an HTLV-l -immortalized tetanus-toxoid-specific CD4+ Tcell line that is profoundly sensitive to the cytopathic effect of HIV-l.2',24 In the absence of rhIL-10, HIVIllB infection reduced the number of viable ATH8 cells to 8% of control over 7 days of culture (Table 5 ). In the presence of 20 U/mL of rhIL-10, some protection from HIV-induced cytopathicity was observed (viable cells averaged 39% of uninfected control). This concentration of rhIL-l0 caused no inhibition of cell proliferation in the absence of HIV infection (1 13% of control), suggesting that the anti-HIV effect was not simply caused by cellular toxicity. In contrast to hIL-IO, rmIL-IO had little or no effect on HIV-induced cytopathicity in this system. Although it should be stressed that the protection afforded by rhIL-l0 in this T-cell line is substantially less than that induced by ddI, a dideoxynucleoside anti-HIV agent (an average of 91% suppression at 20 pmol/L), the results were still suggestive of a modest protective effect.
DISCUSSION
In this study, we have shown that HIV replication in monocytes is inhibited by rhIL-l0 at concentrations that cause little or no cellular toxicity and that do not suppress cytokine secretion in response to LPS. This inhibition was observed with a 2-day exposure to IL-10, starting at the time of viral inoculation as well as 5 or 15 days after viral infection. rhIL-l0 also caused partial suppression of viral production in certain monocytoid or T-cell lines, albeit at higher concentrations. These data indicate that one activity of IL-10 is the suppression of HIV replication in cells of the monocyte lineage. Various concentration of rhlL-l0 or control medium were added to M/M that had been preincubated for 4 days, and stimulation of cytokine secretion with LPS (1 pg/mL) was immediately performed. Twelve hours later, supernatants were harvested for determination of cytokine levels. Results shown are mean GEM) of triplicate determinations. No difference from the results without IL-10 reached statistical significance.
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From In the short period of time since the identification of murine and human IL-10, a number of effects have been found to be mediated by this ~ytokine.'.~~ In particular, IL-10 appears to suppress certain T-cell functions and to decrease the production of certain cytokines by h4/M.2,3,5 However, there remain many unanswered questions as to whether IL-10 production is beneficial or deleterious in various infectious states. In the case of parasitic infections, it has been noted that IL-10 inhibits the production of reactive nitrogen oxides, which are involved in the elimination of intracellular Toxoplasma g~n d i ?~ and the extracellular killing of Schistosoma mansoni by rna~rophages.'~"~ It has been speculated that induction of IL-10 production may be a means by which parasites escape cell-mediated imrn~nity.~' It has been speculated that BCRFl may be a "trapped" cellular gene that may confer a selective advantage to EBV, perhaps by directly contributing to the stimulation of EBV-infected B cells or by helping the EBV-infected cells evade immune s u r~e i l l a n c e .~~~~ It has thus been hypothesized that expression of IL-10-like activity by EBV-infected cells may confer some survival advantage to the virus, either by directly enhancing viral i n f e~t i o n '~.~~ or by aiding the development of an apathogenic chronic carrier state.* More recently, serum IL-10 levels as high as 2,000 pg/mL (roughly 1 to 20 U/mL) have been reported in patients with non-Hodgkin's lymph~rna.~' Interestingly, some of the patients with elevated IL-10 levels were seronegative for EBV, and the source of the IL-IO elevations in patients with lymphoma remains to be determined.
In a murine retroviral model of AIDS, there is evidence to suggest that overexpression of IL-10 may contribute to It is possible that endogenous production of IL-10 in HIVinfected patients has effects on the disease process. As noted above, it has been observed that stimulated peripheral blood mononuclear cells obtained from patients with advanced HIV infection have increased IL-10 production compared with those taken in earlier stages of disease.53 If IL-10 is similarly produced in vivo, it may thus serve to suppress HIV replication in M/M and retard disease progression. It is also possible that IL-IO has a role in the shift from monocytotropic to lymphocytotropic HIV in by providing selective pressure against replication in monocytes and forcing outgrowth of proportionately greater numbers of virus particles from lymphocytes. Further research will be needed to sort out these issues.
By what mechanism does IL-10 act to suppress the infection of M/M by HIV? The results here with late addition of IL-l0 suggest that it may act at one of the late stages of viral replication (ie, after the formation of the provirus). One possible mechanism for the anti-HIV activity of IL-10 may be downregulation of cytokine production (such as TNF-a, GM-CSF, or IL-6), which, in turn, stimulates the later stages of HIV re~lication.~~ Indeed, Poli et a15' have recently reported that, in a system using adherent macrophages, HIV replication could be inhibited by rhIL-10, but, at the same time, this inhibition was reversed by the addition of TNFa. However, under the culture conditions used in the present experiments, rhIL-l0 acted to suppress HIV replication at lower concentration than those required to suppress TNF-a production. Also, under these culture conditions, HIV-infected M/M do not produce detectable amounts of TNF-a or IL-6 (A. Foli and R. Yarchoan, unpublished observation). However, it is still conceivable that very small amounts of these cytokines produced by M/M act in an autocrine manner to stimulate HIV infection. Another mechanism for the action of IL-l0 in suppressing HIV may be through transcriptional activators such as NF-KB,~' or, alternately, increased ribonucleolytic activity (proposed by Bogdan et a159 as the mechanism for IL-10-induced downregulation of cytokine release).
A third mechanism may be through an effect on nucleoside pools or other factors that affect early steps of HIV replication. Although IL-l0 had some ability to suppress HIV replication in chronically infected M/M or monocytoid lines, the effects were most pronounced in the setting of acute infection. The ability of HIV to undergo reverse transcription and form a provirus is dependent on the state of activation of the target cell as well as intracellular nucleoside pools.60,61 E-10 may thus influence the rate of proviral formation through its protean effects on M/M activation. However, it should be noted that the suppression of HIV replication is not simply the result of a toxic effect of IL-l0 on M / M; as seen in these experiments, the anti-HIV effects occurred at concentrations of IL-10 that had little or no effect on cellular viability, protein synthesis, cytokine secretion, phagocytosis, or the ability to present antigen (tetanus toxoid). Given its ability to suppress HIV replication in I", might IL-10 be worth considering as a candidate for antiviral therapy? An additional benefit of IL-IO in this setting may be its ability (at higher concentrations) to suppress the production of TNF-a and IL-6, cytokines that contribute to the pathogenesis of AIDS and its complications.62 However, there would appear to be a number of substantial obstacles to its clinical use in this setting: it acts predominantly in M / M; it enhances immunosuppression; and may promote the development of lymphoma^.^^.^^ Additional studies will be needed to sort these issues out and to determine whether this compound might conceivably have a clinical role, possibly in combination with other drugs or in select subsets of patients. Finally, as we learn about the mechanism for its anti-HIV activity, it may be possible to engineer a separation of this effect from the other immunologic activities of this cytokine.
